Cervical cancer screening in Brazilian Amazon Indigenous women: Towards the intensification of public policies for prevention Authors: Iria Ribeiro Novais, Camila Olegario Coelho, Helymar Costa Machado, Fernanda Surita, Luiz Carlos Zeferino, Diama Bhadra Vale, Antonio Carlos Rosario Vallinoto, Antonio Carlos Rosario Vallinoto, Antonio Carlos Rosario Vallinoto Published: 2023 ABSTRACT BackgroundIndigenous women are vulnerable to cervical cancer. Screening is a strategy to reduce the burden of the disease.ObjectiveTo evaluate the prevalence profile of cervical cancer screening cytological results in Brazilian indigenous women by age and frequency of tests compared to non-indigenous women.MethodsA cross-sectional study evaluating the prevalences of screening test results in indigenous women assisted in the Brazilian Amazon from 2007 to 2019 (3,231 tests), compared to non-indigenous women (698,415 tests). The main outcome was the cytological result. Other variables were frequency, age groups, and population. The frequency was categorized as "1st test", the first test performed by the women in their lifetime, or "screening test," tests from women who had previously participated in screening. Analyzes were based on prevalences by age group and population. We used Prevalence Ratios (PR) and 95% Confidence Intervals for risks and linear regression for trends.ResultsData from the 1st test showed a higher prevalence of Low-grade Squamous Intraepithelial Lesion (LSIL) in indigenous women. Peaks were observed in indigenous under 25, 35 to 39, 45 to 49, and 60 to 64. The prevalence of High-grade Squamous Intraepithelial Lesion or more severe (HSIL+) was low in both groups in women younger than 25. The indigenous HSIL+ prevalence curve showed a rapid increase, reaching peaks in women from 25 to 34 years, following a slight decrease and a plateau. In screening tests, HSIL+ was more prevalent in indigenous from 25 to 39 (PR 4.0,2.3;6.8) and 40 to 64 (PR 3.8,1.6;9.0). In indigenous, the PR of HSIL+ results in screening tests over 1st tests showed no screening effect in all age groups. In non-indigenous, there was a significant effect toward protection in the age groups over 25.ConclusionThis screening study of indigenous women from diverse ethnicities showed a higher prevalence of cytological LSIL and HSIl+ than in non-indigenous women. The protective screening effect in reducing HSIL+ prevalence was not observed in indigenous. Background Indigenous women in Latin America are more vulnerable to cervical cancer than non-indigenous women. The prevalence of precursor lesions is high, cases are diagnosed in advanced stages, incidence and mortality rates are high, and survival is low [1–14]. Despite the variable rates of HPV prevalence, genetic diversity is reported and overlaps with poor knowledge regarding the immunological aspects [2, 8, 11, 13, 15]. The origin of those women points to a diverse ethnicity related to their geographical location and family group origin, which in turn reflects in their sexual reproductive behavior. A central issue common to all groups is the fragility of healthcare access, leading to a high prevalence of diseases influenced by social determinants, such as infectious disease, infant mortality, violence, and cervical cancer [16]. Brazil is estimated to be around one million indigenous people, one-third of whom live in the Amazon region. There are more than 300 ethnicities. The non-profit Organization "Expedicionários da Saúde" (EDS) provides medical care to geographically isolated indigenous populations in the Brazilian Amazon [17]. Since 2004 expeditions have been made in partnership with the Indigenous Secretary of the Ministry of Health. One of the healthcare actions performed is cervical cancer screening through cytology smears, following the Brazilian official recommendation [18]. The slides are processed and analyzed in the cytopathology laboratory of the Women’s Hospital of the University of Campinas (CAISM/Unicamp). This study aimed to analyze the prevalence of abnormal results in cytologic screening tests of indigenous women from the Brazilian Amazon from 2007 to 2019, compared with non-indigenous women. The expectations were to provide a comprehensive profile of high-risk results prevalence by age and to evaluate the screening efficiency. The diversity of ethnicities analyzed may present a broad understanding to support the implementation of the screening recommendations. Methods It was a cross-sectional study evaluating the prevalence of cytological results from cervical cancer screening in indigenous women assisted by a non-profit organization in the Brazilian Amazon from 2007 to 2019. Cytological results were recorded in the Women’s Hospital laboratory database of the University of Campinas, the data source. We compared the indigenous results with tests recorded in the same database from 2007, 2011, 2015, and 2019. The subjects were called "indigenous"–women attended by the organization in remote areas of the Amazon rainforest (S1 Table), and "non-indigenous"–women from the general population using the health care facilities of Campinas and surroundings, whose cytological results were stored in the same lab. The total sample was 3,513 tests from the indigenous and 769,729 tests from non-indigenous women. Cervical cancer prevention in Brazil is based on vaccine and screening actions, both free of charge in the public health system. The vaccine program targets girls and boys from 9 to 14 years old in the two doses schedule (0/6) [19]. Although the coverage in the overall population is around 50% [19], indigenous people’s coverage was over 85% before the pandemic (data available from the Ministry of Health upon request). Overall, screening is cytology-based through an opportunistic program (no personal invitation) targeting women 25 to 64 years old every three years at primary health care (PHC). Precursor lesions are treated in referral facilities by LEEP [18]. Coverage is low in indigenous and non-indigenous people, usually higher following the socio-economic level of the region. Indigenous women may be accessed to cytology by local PHC or non-profit organizations. There is no specific recommendation for indigenous women regarding screening [18]. Indigenous women are unlikely to be treated in their place of origin, especially when living in remote areas of the Amazon rainforest, requiring a complex and articulated framework to access a referral facility. The non-profit organization EDS has carried out two or three annual expeditions to the Brazilian Amazon since 2004, performing low-complexity surgical procedures and attendance in gynecology, obstetrics, pediatric, general surgery, orthopedy, and ophthalmology. Women’s health care includes cervical cancer screening, and some expeditions treat precursor lesions by LEEP. Those actions complement the fragile local opportunistic screening by PHC in the region. Test results were returned to PHC, and abnormal results followed the regular multilevel pathway throughout referral regional facilities to colposcopy and treatment, including those results suggestive of invasive lesions. In indigenous women, only one test suggested invasive lesion. The University of Campinas laboratory analyzes cytology primarily from women who had their test collected in the public health system of Campinas region, comprising a population of nearly three million inhabitants. It is certificated as a high-quality cytology laboratory and performs quality control for other laboratories in São Paulo state. It stores information about the women and the cytological results. The professional who collects the test (physician or nurse) records the clinical data using a form that is submitted to optical reading. The cytology results prevalences are similar to those identified nationally by the central Ministry of Health database [18]. All EDS tests identified in the database from 2007 to 2019 were included. Totals were confronted with documents from the expeditions to corroborate their origin. For comparison, all other tests from the database in 2007, 2011, 2015, and 2019 were included. The exclusion criteria were tests from women previously submitted to hysterectomy; tests collected for purposes other than screening (follow-up of previous abnormal result or post-treatment procedure); unsatisfactory smears according to the Bethesda criteria [18]; and those without information on age or result. In the original collection form, "frequency" was recorded as "first test," "less than one year," "one year," "two years,"…, "five years," and "more than five years." After exclusion criteria were applied, in the category "frequency," those with unknown "frequency" were redistributed by age group and result, and then excluded those reported as "less than one year" because they were considered as "tests collected for purposes other than screening." The outcome variables were the cytological results. Cytopathological reports used in the laboratory follow the Brazilian Nomenclature for Cytopathological Reports [18], based on the Bethesda System. In this study, we categorized results as "Low-grade Squamous Intraepithelial Lesion (LSIL)" or "High-grade Squamous Intraepithelial Lesion or more severe" (HSIL+). HSIL+ corresponded to Squamous Cell Carcinoma, Atypical Glandular Cells, Adenocarcinoma in situ, and Invasive Adenocarcinoma. Because of their low frequency, we grouped those results into one single category. The totals included the results "negative for neoplasia" and "Atypical Squamous Cells (ASC-US–of undetermined significance or ASC-H–which cannot exclude high-grade intraepithelial lesion)". ASC-H was not included as HSIL+ because the database merges all ASC in one category (the categorization as ASC-US or ASC-H is presented written in the original form). The other variables were frequency, age groups, and population (indigenous and non-indigenous). The frequency was categorized as "1st test", the first test performed by the women, or "screening test", tests from women who had previously participated in screening (non-1st test). It is important to note that the data from the 1st test indicates the natural history of the prevalence in that population since they represent tests in women who were not submitted to previous screening/treatment practices. Thus, assuming a high specificity of cytological results, the "1st test" is a proxy of the prevalent lesions in that population. Screening tests indicate the prevalence in women who may have or may not have been submitted to procedures in the cervix that can disrupt the natural history of the disease. In the screening context, a protective effect is expected to reduce the prevalence of precursor or invasive lesions (HSIL+) [20–22]. Statistical analyzes were based on the prevalence of results by age group and population (indigenous and non-indigenous). Prevalences were calculated using as a numerator the number of tests by each result by age group (LSIL or HSIL+), and as a denominator the total number of tests in that age group (any result). The results were presented per 10,000 tests. Prevalence Ratio (PR) and their respective 95% Confidence Intervals (CI) were calculated to relate the variables of interest. Trends were assessed by linear regression. The power of the study was calculated by a significant level of 5% in the group of women in their 1st test. It was used "The SAS System for Windows (Statistical Analysis System), version 9.4." (SAS Institute Inc, 2002–2012, Cary, NC, USA). The project was approved by the "Research and Ethics Committee of the University of Campinas" and by the "National Committee of Ethics in Research" (CONEP) under the number CAAE: 51446421.9.0000.5404. Both Committees waived the need for Informed Consent due to the study’s retrospective nature. Results From the total number of tests, were excluded respectively in indigenous and non-indigenous women: "hysterectomy" 19 and 21,231 tests; "tests collected for purposes other than screening" 222 and 60,780 tests; "unsatisfactory" 38 and 7,394 tests; unknown "age" 7 and 418 tests; and unknown "result" 38 and 7,878 tests. More than one exclusion criterion could be applied to each test. The final sample consisted of 3,231 cytology from indigenous women and 698,415 from non-indigenous women: respectively, 1,162 and 55,954 from women performing the test for the first time (1st test), and 2,069 and 642,461 from women who have already participated in screening (screening test). The power of the study to detect a difference in HSIL+ in their 1st test was 97.6% (0.89% in indigenous versus 0.26% in non-indigenous, β = 0.976). The description of the expeditions and ethnicities covered are displayed on the S1 Table. Table 1 shows the proportions of the aggregated results (LSIL, HSIL+, and totals). Overall, respectively in indigenous and non-indigenous women, the proportion of tests performed in women younger than 25 was 21.7% and 19.4%; from 25 to 39 years 43.1% and 35.7%; from 40 to 64 years 31.6% and 40.4%; and over 64 years 3.6% and 4.6%. The proportion of LSIL results was 0.9% in indigenous and 0.4% in non-indigenous. Of HSIL+ results, it was 0.9% in indigenous and 0.3% in non-indigenous. 10.1371/journal.pone.0294956.t001Table 1Proportion of cervical cancer screening cytological results by age groups in indigenous (3,231 tests) and non-indigenous women (698,415 tests).Age groupLSILHSIL+Total (Neg+ASC+LSIL+HSIL+)IndigNon-indigIndigNon-indigIndigNon-indig < 25 2.1%1.0%0.1%0.3%21.7%19.4% 25 to 39 0.8%0.4%1.4%0.3%43.1%35.7% 40 to 64 0.5%0.1%0.7%0.2%31.6%40.4% > 64 0.0%0.0%0.8%0.3%3.6%4.6% Total 0.9%0.4%0.9%0.3%100.0%100.0%Legend—< 25: women under 25; > 64: women over 64; Neg: Negative; ASC–Atypical squamous cell; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; Indig: Indigenous women; Non-indig: Non-indigenous women. Proportion of cervical cancer screening cytological results by age groups in indigenous (3,231 tests) and non-indigenous women (698,415 tests). Legend—< 25: women under 25; > 64: women over 64; Neg: Negative; ASC–Atypical squamous cell; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; Indig: Indigenous women; Non-indig: Non-indigenous women. We analyzed the PR of LSIL and HSIL+ cytological results in indigenous and non-indigenous women in their 1st test (Table 2) and their screening test (Table 3). Data from the 1st test showed a higher prevalence of LSIL in indigenous women than non-indigenous women: in younger than 25, the PR was 2.0 (CI 1.1;3.6); in 40 to 64 was 9.6 (CI 2.7;34.1); and in older than 64 lower than zero. The prevalence of HSIL+ was low in both groups in women younger than 25. In women aged 25 to 39, the PR of indigenous versus non-indigenous was 3.0 (CI 1.3;6.8). In the oldest age groups, the prevalence in indigenous women was lower, although not significantly (Table 2). 10.1371/journal.pone.0294956.t002Table 2Prevalence ratio of cytological results comparing indigenous and non-indigenous women in their first cervical cancer screening test (1,162 and 55,954 tests, respectively).LSILHSIL+IndigNon-indigIndigNon-indigAge groupP (/10,000)PR (95% CI)P (/10,000)PR (95% CI) < 25 264.8131.32.0 (1.1;3.6)24.017.31.4 (0.2; 9.9) 25 to 39 146.572.32.0 (0.9;4.8)169.856.53.0 (1.3;6.8) 40 to 64 149.515.49.6 (2.7;34.1)84.497.30.9 (0.2;3.2) > 64 0.00.0-134.9233.40.6 (0.1;4.2)Prevalence ratio–indigenous/non-indigenous women.Legend—< 25: women under 25; > 64: women over 64; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; Indig: Indigenous women; Non-indig: Non-indigenous women; P–Prevalence; PR: Prevalence ratio; CI–Confidence Interval). Prevalence ratio of cytological results comparing indigenous and non-indigenous women in their first cervical cancer screening test (1,162 and 55,954 tests, respectively). Prevalence ratio–indigenous/non-indigenous women. Legend—< 25: women under 25; > 64: women over 64; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; Indig: Indigenous women; Non-indig: Non-indigenous women; P–Prevalence; PR: Prevalence ratio; CI–Confidence Interval). 10.1371/journal.pone.0294956.t003Table 3Prevalence ratio of cytological results comparing indigenous and non-indigenous women attending cervical cancer screening (2,069 and 642,461 tests, respectively).LSILHSIL+IndigNon-indigIndigNon-indigAge groupP (/10.000)PR (CI 95%)P (/10.000)PR (CI 95%) < 25 134.886.51.6 (0.6;4.2)0.028.70.6 (0.0;9.8) 25 to 39 53.041.01.3 (0.6;3.0)131.533.14.0 (2.3;6.8) 40 to 64 7.914.20.6 (0.0;7.3)70.718.53.8 (1.6;9.0) > 64 0.03.630.1 (1.0;502.4)0.022.35.0 (0.3;79.2)Prevalence ratio–indigenous/non-indigenous women.Legend—< 25: women under 25; > 64: women over 64; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; Indig: Indigenous women; Non-indig: Non-indigenous women; P–Prevalence; PR: Prevalence ratio; CI–Confidence Interval). Prevalence ratio of cytological results comparing indigenous and non-indigenous women attending cervical cancer screening (2,069 and 642,461 tests, respectively). Prevalence ratio–indigenous/non-indigenous women. Legend—< 25: women under 25; > 64: women over 64; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; Indig: Indigenous women; Non-indig: Non-indigenous women; P–Prevalence; PR: Prevalence ratio; CI–Confidence Interval). Regarding the screening tests, LSIL was more prevalent in indigenous women under 25, although not significantly. HSIL+ prevalences were zero in indigenous younger than 25 and older than 64. The prevalences in indigenous were higher than in non-indigenous women from 25 to 39 (4.0, CI 2.3;6.8) and 40 to 64 (3.8, CI 1.6;9.0) (Table 3). Table 4 presents data on the risk of women who had already participated in screening (screening test) or who were performing their 1st screening test (1st test). No screening effect could be observed in indigenous except for LSIL in women aged 40 to 64 (PR 0.05; CI 0.00;0.81). In non-indigenous, a screening effect toward protection was observed for HSIL+ in women older than 25, more pronounced in women older than 40: PR 0.19 (CI 0.13;0.27) in women aged 40 to 64; and 0.10 (CI 0.06;0.15) in women older than 64. 10.1371/journal.pone.0294956.t004Table 4Prevalence ratio of cytological results in women attending screening or performing their first screening test, in indigenous and non-indigenous women.IndigenousNon-indigenousLSILHSIL+LSILHSIL+PR (CI 95%)PR (CI 95%)PR (CI 95%)PR (CI 95%) < 25 0.51 (0.16;1.62)0.49 (0.02;12.02)0.66 (0.59;0.73)1.65 (1.28;2.14) 25 to 39 0.36 (0.11;1.17)0.77 (0.31;1.96)0.57 (0.44;0.74)0.59 (0.43;0.79) 40 to 64 0.05 (0.00;0.81)0.84 (0.18;3.84)0.91 (0.39;2.13)0.19 (0.13;0.27) > 64 - 0.56 (0.02;13.44)0.85 (0.05;14.43)0.10 (0.06;0.15)Prevalence ratio–screening test/first test.Legend—< 25: women under 25; > 64: women over 64; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; PR: Prevalence ratio; CI–Confidence Interval). Prevalence ratio of cytological results in women attending screening or performing their first screening test, in indigenous and non-indigenous women. Prevalence ratio–screening test/first test. Legend—< 25: women under 25; > 64: women over 64; LSIL: Low grande intra-epithelial lesion; HSIL+: High-grade intra-epithelial lesion or more severe; PR: Prevalence ratio; CI–Confidence Interval). Figs 1 and 2 show the trend curves for the prevalences by age groups regarding their 1st screening test (1st test). In Fig 1 it is possible to compare the LSIL and HSIL+ curves in indigenous versus non-indigenous women, and in Fig 2, the LSIL and HSIL+ curves in each population group. In both LSIL curves, a trend to decrease the prevalence with aging was observed, although significant only in non-indigenous women (p<0.001). The trend was not significant in indigenous women, but peaks of LSIL prevalence were observed in women under 25 and in the age groups of 35 to 39, 45 to 49, and 60 to 64. In both HSIL+ curves, there was a trend towards increasing the prevalence, although significantly only in non-indigenous women. It is possible to observe in the indigenous HSIL+ curve that there is a rapid increase in HSIL+ prevalence, reaching peaks in women from 25 to 34 years old, then a slight decrease, and a plateau after that. Trends of prevalence of LSIL and HSIL+ cytological results in indigenous versus non-indigenous women, according to age groups. P = P-value, by linear regression. Trends of prevalence of LSIL versus HSIL+ cytological results in indigenous and non-indigenous women, according to age groups. P = P-value, by linear regression. Discussion As far as we noticed, this is the more extensive study regarding cervical cancer screening in indigenous women from Latin America. The quality of data allowed for a detailed analysis aiming to contribute to understanding the diseases’ natural history and the impact of screening on indigenous from the Brazilian Amazon region. A higher prevalence of cytological LSIL and HSIl+ was observed among the indigenous, and the results in the screened population point to an urgent need to improve the current screening practice. The evaluation of the results of the woman’s first screening test (1st test) is related to the natural history of cancer. These women were not submitted to previous procedures in the cervix, so considering the high specificity of cytological tests [20, 23], the age-prevalence of results may reflect the course of the prevalent lesion. We found LSIL results twice as prevalent in indigenous than in non-indigenous younger than 25 years. In the age group 40–64, it was 9.6 times more prevalent. Inferring that LSIL represents transient infections, we considered two hypotheses: indigenous women have more exposition to the HPV virus until older ages or the ability to eliminate the virus by indigenous is compromised. Many studies report a higher prevalence of HPV in indigenous women [2, 8–10, 13, 15, 24]. In the Northern Brazilian Amazon, the HPV prevalence was reported at 39.7%, and it was more significant when more isolated the indigenous population [2]. The same authors found a high prevalence of high-risk HPV in indigenous women over 55, data corroborated by other studies [2, 10, 15, 24]. In high-income regions, the age-specific HPV prevalence curve points to a peak in women some years after sexual debut—around 20 years old, and a steady decline with aging related to the immunologic ability to eliminate the infection [25, 26]. A U-shaped prevalence curve is described in Latin American countries and Asia’s lowest-income regions. In sub-Saharian African regions is observed a persistently high HPV prevalence with aging [26]. Those curves might be explained by persistent risk cofactors such as smoking, HIV, multiparity, etc. In our study, the indigenous results curves were more consistent with those HPV curves related to low-income regions. The HPV prevalence genotype may also interfere. It is well-known that the time to HPV elimination varies according to the genotype [25]. Previous studies show a wide range of HPV subtypes in indigenous, the most prevalent types 6, 11, 16, 18, 31, 33, 45, 53, and 58 [2, 7, 11, 15, 24, 27–30]. The national vaccination program in Brazil introduced prophylaxis to HPV in 2014 and currently vaccinates girls and boys from 9 to 14 years old. The estimated coverage of indigenous in this target age is over 80% [31]. It is improbable women in this study may have been vaccinated. Considering the high LSIL prevalence in older indigenous women observed in this study, the known expected impact of the HPV vaccine, and the ability to reach high coverage vaccine rates, we believe our results should raise the debate to extend the HPV vaccine to older indigenous groups to avoid new infections and boost immunity. We have found the prevalence of HSIL+ low in women younger than 25 in both groups (indigenous and non-indigenous). It supports the recommendation of the Brazilian Ministry of Health not to screen women before 25 years old. Speck et al. in 2015 claimed that indigenous women should start screening earlier, based on the finding of 0.5% of HSIL cytology result in indigenous women from Xingu, Brazilian Western-Center region, in women 12–24 years old [14]. We found the HSIL+ prevalence 24/10.000 tests in women under 25, which is lower than in the previous study. We must consider that our sample contemplates several ethnic indigenous groups from many regions of the Amazon rainforest, more representative of the indigenous people than the previous study. Nevertheless, we believe that even 0.5% is a shallow rate and does not justify anticipating screening, considering the high rates of HSIL regression in women under 30, more significant in women under 25 [32, 33]. The small benefit of screening at very younger ages should be counterbalanced by the preterm risks associated with identifying precursor lesions in this group [34]. HSIL+ was at least three times more frequent in indigenous women compared to non-indigenous in both 1st test (PR 3.0, 1.3;6.8 in women 25–39) and screening test (PR 4.0, 2.3;6.8 in women 25–39; PR 3.8, 1.6;9.0 in women 40–64). Although no study in Brazil compares indigenous versus non-indigenous women, some studies confirm the high prevalence of precursor lesions in indigenous [2, 5, 7, 14]. In Northern Amazon, one study found an HSIL prevalence of 10.9% in Yanomami women and 2.5% in Macuxi and Wapishana women [2]. Interesting to note that Yanomami women is a group of recent contact with the non-indigenous population. The high LSIL prevalence also reinforces the previous arguments of immunologic decreased ability to eliminate the virus. It indicates that indigenous women are more vulnerable to developing precursor lesions. It highlights the need for specific recommendations on screening. The screening effect was evaluated by comparing the results of screening tests versus 1st tests. In indigenous women, no effect of screening was observed in HSIL+ results. However, in non-indigenous women, as expected, a protective screening effect in preventing HSIL+ was observed in women over 25, more pronounced over 40: 80% protection in women aged 40 to 64 years and 90% in women over 64 years old. One explanation for not observing the screening effect for HSIL+ in indigenous women is the limited sample. However, several factors contribute to the hypothesis that screening in the last decades in the indigenous population was of low efficiency. The first argument is the high prevalence of cervical cancer observed in indigenous women [3, 12, 35]. Renna-Junior et al. showed that indigenous women have two times more chance of being diagnosed in advanced stages when compared to the usual risk population [36]. Second, the evidence regarding screening coverage in indigenous women points to wide rate ranges [2, 7, 37–39], indicating irregular screening and non-standardized actions. Another attractive argument is indigenous behavior. Some authors point to sexual behavior in indigenous favoring cervical cancer risk factors [6, 10, 11, 27, 28, 36, 39–41]. Indeed, there are anthropologic barriers that might hamper willingness to screen. A study with indigenous oncologic patients found that 15% of cancer women refuse treatment [1]. We hypothesize that access to screening practices and treatment of precursor lesions is the main challenge to overcoming screening in indigenous women. In a simplistic model, currently, there are two demographic branches of the indigenous people: one living in indigenous territories in rainforest communities and another living in poor areas of urbanized regions. In the first scenario, indigenous health care is accessed through actions managed by governmental programs or by non-profit organizations. In these settings, the barriers are the region’s geography, limiting health care, and non-sustainable activities. Regarding the indigenous living in poor urban areas, those women accumulate the vulnerability related to social determinants, ethnicity, and the fragility of health systems observed in low-income regions—intersectionality. Both scenarios justify the high relevance of cervical cancer as a public health problem in indigenous women’s health. The demographic register of the indigenous health system is a powerful tool to implement and deliver sustainable strategies when planning a specific cervical cancer screening program for this vulnerable population. Our study has a great diversity of ethnicities of indigenous women from the Brazilian Amazon Rainforest. So, it may be representative of a great variety of indigenous populations. As far as we know, it is the larger sample of cytological results in the context of cervical cancer screening, and the information available makes it possible to trace the detailed profile of the screening characteristics of the population. Aggregated data should not be interpreted as an attempt to reduce the relevance of the ethnicity diversion but rather to support common strategies to guide public policies. Another strength is that the same high-quality laboratory has read all tests. The main limitation is the absence of follow-up in the results since a histological diagnosis would result in a more accurate figure of the natural history inferred. However, considering the paucity of studies on this population, our results should encourage and support control strategies to overcome the challenges. Conclusions A higher prevalence of cytological LSIL and HSIl+ was observed among indigenous women. The protective screening effect in reducing HSIL+ prevalence was not observed in indigenous. The results suggest evaluating the vaccine age group and an urgent need to improve access to screening practices in Brazilian indigenous women. Supporting information Description of health expeditions with screening activities in indigenous women from the Brazilian Amazon from 2007 to 2019. (DOCX) Click here for additional data file. 5 Jul 2023 PONE-D-23-11232Cervical Cancer Screening in Brazilian Amazon Indigenous Women: a wakeup call to expand vaccination and improve access to cervical cancer prevention practicesPLOS ONE Dear Dr. Vale, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 19 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Antonio Carlos Rosario Vallinoto, Ph.D. Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Acknowledgments Section of your manuscript: “IRN was funded by a grant from the "Coordenação de Aperfeiçoamento de Pessoal de Nível Superior" (CAPES) for her Master's degree.” We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: “The author(s) received no specific funding for this work.” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 3. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. [The manuscript is included in a Master Thesis to be defended and published on the University of Campinas website. Results were accepted at the International Cancer Screening Network (ICSN) 2023, to be helded in June 2023.] Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript. 4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No Reviewer #3: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The manuscript presents unpublished data regarding screening tests for cervical cancer in included indigenous and non-indigenous women, with a considerable sample number. It has scientific and sacred merit in public health. However, it is important to review some points to know: Title – The data presented do not support the inference of expansion of vaccination. It would be interesting to adjust and place: an alteration for the intensification of public policies for the prevention of CC. The study does not present data related to the occurrence of CC in the investigated populations. Methodology: 1) What is the Nomenclature system for cytopathological reports adopted in the Program? Bethesda or Brazilian Nomenclature for Cytopathological Reports? It is necessary to insert this information in the methodology. 2) The following outcome variables were used: LSIL, HSIL, squamous cell carcinoma, atypical glandular cells, adenocarcinoma in situ and invasive adenocarcinoma and smears without cytological alterations or normal. However, the frequency of these events was not described in the results or in the tables. Results 1) What is the minimum and maximum age of the participants involved in the study? It is necessary to insert this information in the text. 2) Were there cases of neoplasia in the investigated populations? 3) Table 01 presents only the cytological results (low and high grade lesion) according to age group. It does not present the general characteristics of the examined population. Likewise, it does not inform all the variables considered as an outcome, which were described in the methodology (LSIL, HSIL, Squamous cell carcinoma, atypical glandular cells, adenocarcinoma in situ and invasive adenocarcinoma and smears without cytological changes or normal). These data should all be considered in epidemiology studies and in cervical cancer screening. 4) What are the prevalence rates of cytological changes in the group of women who were screened for cervical cancer? Table 2 does not describe raw frequency or prevalence data for these outcomes. 5) In the Tables, it is necessary to insert the raw prevalence data in the investigated population, the prevalence rate and also the “p” value obtained with the statistical analysis. Discussion 1) 1st Paragraph - The data collected in the present study are not enough to understand the natural history of the disease, as they do not provide information about the follow-up of the participants, evolution or regression of the lesions, therapeutic interventions, nor do they consider the intrinsic factors of the host . It is necessary to adjust/remove this statement in the discussion. 2) 3rd Paragraph - The prevalence rate is not enough to assess the magnitude of the risk, which is achieved through odds ratio. Thus, it is not possible to state that the prevalence is twice as high, but rather that there is a greater probability of occurrence of the event (LSIL) in indigenous women, as PR values above 1 demonstrate a positive association between the events. Therefore, I reinforce the idea that it is necessary to adjust tables 02 and 03, with the insertion of data on prevalence, prevalence rates and p value. As well as the statistical method employed. 3) 4th Paragraph - The study did not aim to evaluate the prevalence of HPV in the examined groups and its correlation with the development of intraepithelial lesions. Thus, it is important to consider in the discussion aspects related to prevalence rates of cytological results (LSIL and HSIl) in the general population and in indigenous populations obtained in other studies conducted in Brazil and in other countries. 4) 5th Paragraph – It is not possible to infer the protective effect of carrying out the screening test for cervical cancer screening in the present study, as there is no description of the cases of cancer in the examined group, there was follow-up of patients to assess the progression of high-grade lesions to cancer. Reviewer #2: The manuscript “Cervical Cancer Screening in Brazilian Amazon Indigenous Women: a wakeup call to expand vaccination and improve access to cervical cancer prevention practices” by Novais and collaborators, aims to evaluate the prevalence profile of cytological results of cervical cancer screening in Brazilian indigenous women by age and frequency of examinations compared to non-indigenous women. For this purpose, tests performed on indigenous women assisted in the Brazilian Amazon from 2007 to 2019 (3,231 tests) were used, which were compared with the results observed in non-indigenous women (698,415 tests) in the same period. It is an important study from an epidemiological and public health point of view, whose results will serve to reinforce and support the adoption of more appropriate public health policies aimed at health care for indigenous peoples in Brazil. It therefore deserves to be published. The study addresses indigenous peoples who exhibit remarkable biological, linguistic and cultural diversity, directly related to the origins and evolutionary events they experienced during their migration in the American continent, and who currently have different socioeconomic realities resulting from contact with non-indigenous people. In this context, analyzing the results globally is obviously important as a parameter or indicator of the health status of indigenous women, but in my view it fails to address the impact of local (regional), ethnic (biological) and sociocultural realities on the prevalence of changes cytology in indigenous people. In the Amazon there are at least 170 indigenous peoples or ethnic groups, the majority living in villages, but with different socioeconomic realities resulting from contact with non-indigenous people, as mentioned above, and a fraction living in urban contexts, generally subjected to macro-social changes imposed by life in cities, with changes in the traditional indigenous lifestyle, which obviously has an impact on their patterns of illness. Therefore, I consider it essential to analyze the data separately by ethnicity or indigenous people, as I imagine that this information is available in the project's database. This is very important even to assess the efficiency of health care in the different Special Indigenous Health Districts (DSEI), which are the units responsible for health care for indigenous peoples, regionally. In the same way, I consider it important to analyze the data separating indigenous villagers from urban indigenous people, if applicable. Another question refers to the “wakeup call to expand vaccination”, because, unless I'm mistaken, no molecular test was carried out to verify the circulating HPV serotypes in the indigenous people, and whether these types are being covered by the vaccine that is offered to the indigenous people. There is also no data on the vaccination coverage of the indigenous people described in the work, if they were vaccinated, how many doses they received, and the age groups contemplated with the vaccination. These are data that I consider important to help in the evaluation of vaccination against HPV and its expansion, if applicable, in indigenous women. I also suggest checking the nomenclature of the cytological results according to what is recommended by the Brazilian nomenclature for cervical cytopathological results in relation to the description of HSIL+. Still on this, I consider it inappropriate to use abbreviations in the abstract of the work, as it makes it difficult for the reader who is not familiar with the subject to understand. Another minor and punctual question refers to considering that “Indigenous women are vulnerable to cervical cancer”. It seems to me that it is a question of assessing whether they are more or less vulnerable than non-indigenous women, since they are also vulnerable, as far as I know, and under what conditions does indigenous women become more or less vulnerable, which involves aspects biological and sociocultural and environmental. In principle, these are my comments and contributions on the manuscript. Reviewer #3: The article seeks an important approach for proposing and monitoring strategies to expand vaccination and improve access to cervical cancer prevention practices. It presents a large number of indigenous and non-indigenous women enrolled and compares the prevalence of initial and more advanced lesions in the progression to cervical cancer, also stratifying by age group. Some adjustments are necessary to give greater coherence to the objectives and conclusions of the article. The most important of these is the lack of information about vaccination of women enrolled as participants. It is not possible to accurately discuss prevention and expansion of vaccination when specific information about vaccination on the study population is not known. As the authors group more advanced lesions (HSIL+), the terms “cervical cancer” and “cervical intraepithelial neoplasia” lose relevance and should not be included as keywords. It is not possible to define the rigor in the classification of “indigenous”, since the authors do not define which areas and the criteria that define them as “remote areas of the Amazon rainforest”. In the discussion, we found the information that “there are two demographic branches of the indigenous people: one living in indigenous territories in rainforest communities and another living in poor areas of urbanized regions“. It would be interesting to carry out the analysis by subcategorizing these two demographic branches. The addition of a map identifying the studied populations is strongly suggested. It is recommended to quantitatively list the number of women excluded from each group by each exclusion criterion. Data analyzed without vaccination information do not support the conclusion “The results suggest expanding the vaccine age group and an urgent need to improve access to screening practices in Brazilian indigenous women.” In “Availability of data and materials”, replace “availabel” with “available”. In the legend of tables 1 and 2, replace “Non-indigenous women” with “Non-indig: Non-indigenous women”. It is necessary to standardize the terms “1st test” and “screening test”, in order to avoid confusion. Sometimes we find “non-first test”, “test for the first time”, “first screening test”, “first cervical cancer screening test”, “cancer screening”. In the legend of Table 4, it is suggested to remove “Indig: Indigenous women; Non-indigenous women; P – Prevalence;”. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: Igor Brasil-Costa ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 2 Oct 2023 Response to reviewers PONE-D-23-11232 Dear Editor and Reviewers. Thanks for the opportunity to review the manuscript. Your valuable comments and corrections improved its quality. The answers to the queries are in the following text. Best regards, The corresponding author. Journal requirements: 1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf R: Adjusted. 2) Thank you for stating the following in the Acknowledgments Section of your manuscript: "IRN was funded by a grant from the "Coordenação de Aperfeiçoamento de Pessoal de Nível Superior" (CAPES) for her Master's degree." We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "The author(s) received no specific funding for this work." Please include your amended statements within your cover letter; we will change the online submission form on your behalf. R: Dear editor. The support by CAPES was made as a scholarship to the first author during her Master's. It is true that "The author(s) received no specific funding for this work." There is no direct funding for the study. The national agency for post-graduation support (CAPES) requires the following statement in the Acknowledgments section on every paper published by a post-graduation student: "This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001". We will change this information for the Funding Statement section. 3) We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. [The manuscript is included in a Master Thesis to be defended and published on the University of Campinas website. Results were accepted at the International Cancer Screening Network (ICSN) 2023, to be helded in June 2023.] Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript. R: Some of the results of this study were presented as a poster at the ICSN Conference. The Conference did not publish the Anais. The manuscript in its original form was in the results section of the Master Thesis of IRN, as one of the products of her Master's. In our post-graduation program, a submitted paper is a condition for the Master's defense. The Master's was defended in May, and the University stores all the thesis copies in an online repository after an embargo of one year. It was not peer-reviewed but will be formally published on the website as the entire thesis AFTER MAY 2024. As usual, if the paper is accepted, we will submit a permission statement before it. We added that information to the cover letter. 4) We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. R: We deposited metadata at https://doi.org/10.25824/redu/9BLFCK, and added this information on the manuscript. 5) Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. R: Corrected. Reviewer #1 1) Title – The data presented do not support the inference of expansion of vaccination. It would be interesting to adjust and place: an alteration for the intensification of public policies for the prevention of CC. The study does not present data related to the occurrence of CC in the investigated populations. R: Thanks for the suggestion. We replaced by "towards the intensification of public policies for the prevention." 2) Methodology: 1) What is the Nomenclature system for cytopathological reports adopted in the Program? Bethesda or Brazilian Nomenclature for Cytopathological Reports? It is necessary to insert this information in the methodology. R: We clarified this issue in methoods section – "The outcome variables were the cytological results. Cytopathological reports used in the laboratory follows the Brazilian Nomenclature for Cytopathological Reports, based on the Bethesda System (ref). In this study we categoryzed results as "Low-grade Squamous Intraepithelial Lesion (LSIL)…" 3) Methodology: 2) The following outcome variables were used: LSIL, HSIL, squamous cell carcinoma, atypical glandular cells, adenocarcinoma in situ and invasive adenocarcinoma and smears without cytological alterations or normal. However, the frequency of these events was not described in the results or in the tables. R: We only use the three categories – LSIL, HSIL+, and total as variables. We agree that this information was not clear throughout the methods and results. We adjusted the text on methods: "In this study, we categorized results as "Low-grade Squamous Intraepithelial Lesion (LSIL)" or "High-grade Squamous Intraepithelial Lesion or more severe" (HSIL+). HSIL+ corresponded to Squamous Cell Carcinoma, Atypical Glandular Cells, Adenocarcinoma in situ, and Invasive Adenocarcinoma. Because of their low frequency, we grouped those results into one single category."; and in the results, we changed the introduction of Table 1: "Table 1 shows the proportions of the aggregated results (LSIL, HSIL+, and totals)." 4) Results - 1) What is the minimum and maximum age of the participants involved in the study? It is necessary to insert this information in the text. R: According to the Ethics Committee, the minimum age of indigenous women screened is sensitive data. We displayed only aggregated data. Screening in Brazil is opportunistic, so, despite the recommendation of screening women over 25, no control prevents a healthcare worker from screening younger women. In fact, as we stated in the discussion, previous studies recommended anticipating screening in indigenous women. 5) Results - 2) Were there cases of neoplasia in the investigated populations? R: We completed the information on methods: "Tests results were returned to PHC, and abnormal results followed the regular multilevel pathway throughout referral regional facilities to colposcopy and treatment, including results suggestive of invasive lesions. In indigenous women, only one test suggested invasive lesion." 6) Results - 3) Table 01 presents only the cytological results (low and high grade lesion) according to age group. It does not present the general characteristics of the examined population. Likewise, it does not inform all the variables considered as an outcome, which were described in the methodology (LSIL, HSIL, Squamous cell carcinoma, atypical glandular cells, adenocarcinoma in situ and invasive adenocarcinoma and smears without cytological changes or normal). These data should all be considered in epidemiology studies and in cervical cancer screening. R: We answered these issues previously with some adjustments to the text. We only use the three categories – LSIL, HSIL+, and total as variables. We agree that this information was not clear throughout the methods and results. We adjusted the text on methods. 7) Results - 4) What are the prevalence rates of cytological changes in the group of women who were screened for cervical cancer? Table 2 does not describe raw frequency or prevalence data for these outcomes. R: In tables 2 ad 3, prevalences are presented in the columns "P" by 10,000 tests. We choose to present data as prevalence instead of frequencies because we believe prevalence is a stronger indicator and demonstrates the load of risk to the data. 8) Results - 5) In the Tables, it is necessary to insert the raw prevalence data in the investigated population, the prevalence rate and also the "p" value obtained with the statistical analysis. R: We stated on methods that we choose to present data as prevalence rate ("P" in the tables). We did not display the raw figures of the test because we think it is not as informative as prevalence data, which is much more sophisticated as a risk indicator. The p-value was calculated in the regression analysis presented in the figures. To compare prevalence rates, we choose the prevalence ratio with confidence interval as a measure of risk (PR (95% CI). 9) Discussion - 1) 1st Paragraph - The data collected in the present study are not enough to understand the natural history of the disease, as they do not provide information about the follow-up of the participants, evolution or regression of the lesions, therapeutic interventions, nor do they consider the intrinsic factors of the host . It is necessary to adjust/remove this statement in the discussion. R: Thanks for helping us to clarify this issue. It was not our intention to claim our data as the corn data regarding the natural history of the disease, but only to contribute and support the knowledge regarding this issue. But we strongly believe in the importance of this data in face of the scarcity of the literature in this setting. We agree the writing may have given a wrong impression. We made adjustments throughout the text. Regarding the 1st paragrapf of the discussion, we wrote: "The quality of data allowed for a detailed analysis AIMING TO CONTRIBUTE TO THE UNDERSTANDING of the diseases' natural history and the impact of screening on indigenous from the Brazilian Amazon region." 10) Discussion - 2) 3rd Paragraph - The prevalence rate is not enough to assess the magnitude of the risk, which is achieved through odds ratio. Thus, it is not possible to state that the prevalence is twice as high, but rather that there is a greater probability of occurrence of the event (LSIL) in indigenous women, as PR values above 1 demonstrate a positive association between the events. Therefore, I reinforce the idea that it is necessary to adjust tables 02 and 03, with the insertion of data on prevalence, prevalence rates and p value. As well as the statistical method employed. R: We did not use the prevalence rate to assess the magnitude of risk when comparing the prevalence rates. We used PREVALENCE RATIO with confidence intervals – the statistical method employed, a well-known measure of risk in clinical epidemiology. In methods, we described the statistics used in the study. 11) Discussion - 3) 4th Paragraph - The study did not aim to evaluate the prevalence of HPV in the examined groups and its correlation with the development of intraepithelial lesions. Thus, it is important to consider in the discussion aspects related to prevalence rates of cytological results (LSIL and HSIl) in the general population and in indigenous populations obtained in other studies conducted in Brazil and in other countries. R: We conducted a systematic review regarding indigenous women in Latin America and found no manuscript comparing non-indigenous and indigenous prevalence. We included in the discussion: "Although no study in Brazil compares indigenous versus non-indigenous women, some studies confirm the high prevalence of precursor lesions in indigenous [2,5,7,14]. In Northern Amazon, one study found an HSIL prevalence of 10.9% in Yanomami women and 2.5% in Macuxi and Wapishana women (Fonseca). Interesting to note that Yanomami women are a group of recent contact with the non-indigenous population. The high LSIL prevalence also reinforces the previous arguments of immunologic decreased ability to eliminate the virus." 12) Discussion - 4) 5th Paragraph – It is not possible to infer the protective effect of carrying out the screening test for cervical cancer screening in the present study, as there is no description of the cases of cancer in the examined group, there was follow-up of patients to assess the progression of high-grade lesions to cancer. R: Long-term outcomes are very difficult to achieve and is possible to use intermediary end-points as surrogates. Our aim was to evaluate the screening actions in the context of giving support to implementing public policies. In the literature there are several examples of audits and recommendations using surrogates to evaluate screening programs. We modified on the citied paragraph: "However, in non-indigenous women, as expected, a protective screening effect in preventing HSIL+ was observed in women over 25, more pronounced over 40… " Reviewer #2 1) It is an important study from an epidemiological and public health point of view, whose results will serve to reinforce and support the adoption of more appropriate public health policies aimed at health care for indigenous peoples in Brazil. R: Thanks for the important comment. It is in line with our thoughts. 2) The study addresses indigenous peoples who exhibit remarkable biological, linguistic and cultural diversity, directly related to the origins and evolutionary events they experienced during their migration in the American continent, and who currently have different socioeconomic realities resulting from contact with non-indigenous people. In this context, analyzing the results globally is obviously important as a parameter or indicator of the health status of indigenous women, but in my view it fails to address the impact of local (regional), ethnic (biological) and sociocultural realities on the prevalence of changes cytology in indigenous people. In the Amazon there are at least 170 indigenous peoples or ethnic groups, the majority living in villages, but with different socioeconomic realities resulting from contact with non-indigenous people, as mentioned above, and a fraction living in urban contexts, generally subjected to macro-social changes imposed by life in cities, with changes in the traditional indigenous lifestyle, which obviously has an impact on their patterns of illness. Therefore, I consider it essential to analyze the data separately by ethnicity or indigenous people, as I imagine that this information is available in the project's database. This is very important even to assess the efficiency of health care in the different Special Indigenous Health Districts (DSEI), which are the units responsible for health care for indigenous peoples, regionally. In the same way, I consider it important to analyze the data separating indigenous villagers from urban indigenous people, if applicable. R: We totally agree with your comments and it was one of our objectives while writing the study protocol. However, when analysing it we found out we would fail in qualifying the analysis when limiting the samples. In fact, in a systematic review we are conducting about the topic, we observe that the majority of the papers present data by ethnicity, and those results are fragile to support hypothesis and public policies (small sample). We realize that grouping results would give more important information and the robusteness of the analysis would make the recommendations stronger. We added on the limitation: "Aggregated data should not be interpreted as an attempt to reduce the relevance of the ethnicity diversion, but rather to support common strategies to guide public policies." 3) Another question refers to the "wakeup call to expand vaccination", because, unless I'm mistaken, no molecular test was carried out to verify the circulating HPV serotypes in the indigenous people, and whether these types are being covered by the vaccine that is offered to the indigenous people. There is also no data on the vaccination coverage of the indigenous people described in the work, if they were vaccinated, how many doses they received, and the age groups contemplated with the vaccination. These are data that I consider important to help in the evaluation of vaccination against HPV and its expansion, if applicable, in indigenous women. R: Thanks for your comment and perspective. We added in the discussion: "The national vaccination program in Brazil introduced prophylaxis to HPV in 2014 and currently vaccinates girls and boys from 9 to 14 years old. The estimated coverage of indigenous in this target age is over 80% [31]. It is improbable women in this study may have been vaccinated. Considering the high LSIL prevalence in older indigenous women observed in this study, the known expected impact of the HPV vaccine, and the infrastructure and ability to reach high coverage vaccine rates, we believe our results should raise the debate to extend HPV vaccine to older indigenous groups to avoid new infections and boost immunity." 4) I also suggest checking the nomenclature of the cytological results according to what is recommended by the Brazilian nomenclature for cervical cytopathological results in relation to the description of HSIL+. R: We agree it was not clear in the methods. As also commented by Reviewer 1, we adjusted the text on methods: "In this study, we categorized results as "Low-grade Squamous Intraepithelial Lesion (LSIL)" or "High-grade Squamous Intraepithelial Lesion or more severe" (HSIL+). HSIL+ corresponded to Squamous Cell Carcinoma, Atypical Glandular Cells, Adenocarcinoma in situ, and Invasive Adenocarcinoma. Because of their low frequency, we grouped those results into one single category." 5) Still on this, I consider it inappropriate to use abbreviations in the abstract of the work, as it makes it difficult for the reader who is not familiar with the subject to understand. R: Adjusted. 6) Another minor and punctual question refers to considering that "Indigenous women are vulnerable to cervical cancer". It seems to me that it is a question of assessing whether they are more or less vulnerable than non-indigenous women, since they are also vulnerable, as far as I know, and under what conditions does indigenous women become more or less vulnerable, which involves aspects biological and sociocultural and environmental. R: We agree and adjusted the text (introduction): "Indigenous women in Latin America are more vulnerable to cervical cancer than non-indigenous women." Reviewer #3 1) Some adjustments are necessary to give greater coherence to the objectives and conclusions of the article. The most important of these is the lack of information about vaccination of women enrolled as participants. It is not possible to accurately discuss prevention and expansion of vaccination when specific information about vaccination on the study population is not known. R: Thanks for the valuable comment. We were more discreet regarding the vaccination aspects throughout the text and, as also suggested by reviewer 2, we added to the discussion: "The national vaccination program in Brazil introduced prophylaxis to HPV in 2014 and currently vaccinates girls and boys from 9 to 14 years old. The estimated coverage of indigenous in this target age is over 80% [31]. It is improbable women in this study may have been vaccinated. Considering the high LSIL prevalence in older indigenous women observed in this study, the known expected impact of the HPV vaccine, and the infrastructure and ability to reach high coverage vaccine rates, we believe our results should raise the debate to extend HPV vaccine to older indigenous groups to avoid new infections and boost immunity." 2) As the authors group more advanced lesions (HSIL+), the terms "cervical cancer" and "cervical intraepithelial neoplasia" lose relevance and should not be included as keywords. R: We choose to keep those terms because the study refers to those general topics rather than being related to these specific outcomes. 3) It is not possible to define the rigor in the classification of "indigenous", since the authors do not define which areas and the criteria that define them as "remote areas of the Amazon rainforest". In the discussion, we found the information that "there are two demographic branches of the indigenous people: one living in indigenous territories in rainforest communities and another living in poor areas of urbanized regions ". It would be interesting to carry out the analysis by subcategorizing these two demographic branches. The addition of a map identifying the studied populations is strongly suggested. R: Thanks for noting. We added a table describing the expeditions and ethnicities covered. On results: "The description of the expeditions and ethnicities are displayed on S1 table." 4) It is recommended to quantitatively list the number of women excluded from each group by each exclusion criterion. R: In the methods it was added: In the original collection form, "frequency" was recorded as "first test," "less than one year," "one year," "two years,"…, "five years," and "more than five years." After exclusion criteria were applied, in the category "frequency," those with unknown "frequency" were redistributed by age group and result, and then excluded those reported as "less than one year" because they were considered as "tests collected for purposes other than screening." And on the results it was added: From the total number of tests, those were excluded in indigenous and non-indigenous women, respectively: hysterectomy 19 and 21,231 tests; tests collected for purposes other than screening 222 and 60,780 tests; unsatisfactory 38 and 7,394 tests; and without information on age 7 and 418 tests; or result 38 and 7,878 tests. More than one exclusion criteria could be applied to each test. 5) Data analyzed without vaccination information do not support the conclusion "The results suggest expanding the vaccine age group and an urgent need to improve access to screening practices in Brazilian indigenous women." R: We agree we should be more discreet in the conclusion. We added the information on vaccination to the discussion as previously commented and changed the sentence to: "the results suggest EVALUATING the vaccine age group…" 6) In "Availability of data and materials", replace "availabel" with "available". R: Thanks for noting. Corrected. 7) In the legend of tables 1 and 2, replace "Non-indigenous women" with "Non-indig: Non-indigenous women". R: Corrected. 8) It is necessary to standardize the terms "1st test" and "screening test", in order to avoid confusion. Sometimes we find "non-first test", "test for the first time", "first screening test", "first cervical cancer screening test", "cancer screening". R: Thanks for noting. We went through all the documents adjusting the terms. 9) In the legend of Table 4, it is suggested to remove "Indig: Indigenous women; Non-indigenous women; P – Prevalence;". R: Corrected. Submitted filename: Indig_Response_PLOSOne.docx Click here for additional data file. 13 Nov 2023 Cervical cancer screening in Brazilian Amazon Indigenous women: towards the intensification of public policies for prevention PONE-D-23-11232R1 Dear Dr. Vale, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Antonio Carlos Rosario Vallinoto, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: (No Response) ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: (No Response) ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes Reviewer #3: (No Response) ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: (No Response) ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: The authors adequately addressed my comments and suggestions made previously and I consider that the manuscript is acceptable for publication, providing important data on a prevalence profile of cytological exam results in cervical cancer screening in indigenous women, which will contribute important information for the adoption of more appropriate public health policy methods for health care for Brazilian indigenous women. Reviewer #3: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Jacqueline Cortinhas Monteiro Reviewer #2: No Reviewer #3: Yes: Igor Brasil-Costa ********** 1 Dec 2023 PONE-D-23-11232R1 Cervical cancer screening in Brazilian Amazon Indigenous women: towards the intensification of public policies for prevention. Dear Dr. Vale: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Antonio Carlos Rosario Vallinoto Academic Editor PLOS ONE